Evotec Appoints Dr. Ashiq H. Khan as Chief Commercial Officer "Ashiq has demonstrated tremendous success driving growth in innovative areas like robotics, artificial intelligence and cutting-edge drug discovery platforms. His expertise is essential for executing the next stage of Evotec's transformation as a responsive drug discovery and development engine built around high-value services and capabilities. We are excited to have someone with his experience in recognizing and ...

PresentationSwayampakula RamakanthH.C. Wainwright & Co, LLC, Research Division Good morning. I'm RK, a senior sell-side biotech analyst at H.C. Wainwright. So -- and we are thrilled to be hosting Precigen for this fireside chat this morning. So 2025 has been a transformational year for Precigen, marked by the landmark FDA approval of PAPZIMEOS, the first immunotherapy for adult RRP. So as we sit here in late March of 2026, the company has officially transitioned into a commercial stage entity reporting its ...

In this article, we will take a look at 10 Stocks That Could 10X Over the Next 5 Years.March appears to be finishing on a low note, with the S&P 500 dipping on March 30, pulled down by new rises in oil prices and a sharp decline in technology, as traders moved on from Fed Chair Jerome Powell’s remarks on inflation. The broad-based index fell 0.39%, marking the third consecutive losing session, at 6,343.72. The index’s losses took it slightly over 9% off its closing high, with drops in the technology sector ...

New York, New York--(Newsfile Corp. - March 31, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If you purchased Nektar securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee ar ...

Ten stocks soared by double digits on Tuesday, outperforming Wall Street, as investors took heart from a flurry of corporate and industry developments, including acquisition deals.Meanwhile, the three benchmark indices all finished in the green, with the Nasdaq soaring 3.83 percent, followed by the S&P 500 gaining 2.91 percent, and the Dow Jones jumping 2.49 percent.In this article, we spotlight the 10 top-performing companies on Tuesday and detail the reasons behind their gains.To come up with the list, we ...

SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Atara Biotherapeutics, Inc. (NASDAQ: ATRA) securities between May 20, 2024 and January 9, 2026. Atara develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the U.S. and the United Kingdom (“U.K.”). The Company’s lead product candidate is tabelecleucel (also referred to as tab-cel or EBVALLO), a ...

New York, New York--(Newsfile Corp. - March 31, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025 and October 31, 2025, inclusive (the "Class Period"), of the important April 13, 2026 lead plaintiff deadline.SO WHAT: If you purchased uniQure ordinary shares during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrang ...

Firm Reminds Investors of April 13 Lead Plaintiff Deadline in Pending Securities Class Action SAN FRANCISCO, March 31, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is updating its investigation into uniQure N.V. (NASDAQ: QURE) a series of extraordinary rebukes by Food and Drug Administration (FDA) officials. This investigation follows the filing of a securities class action lawsuit seeking to represent investors who purchased or otherwise acquired uniQure ordinary shares betwe ...

Scientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not re ...

<!doctype html> <!-- For structured data --> <!-- For language declaration --> MREO Deadline: MREO Investors with Losses in Excess of $100K Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit <!-- Additional Authorable Meta tags --> Accessibility StatementSkip NavigationNEW YORK, March 31, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares ("ADS") of Mereo BioPharma Group plc (NASDAQ: MREO) between June 5, 2023 and ...